[go: up one dir, main page]

MA49456A - Composés et procédés pour le traitement de nafld et de nash - Google Patents

Composés et procédés pour le traitement de nafld et de nash

Info

Publication number
MA49456A
MA49456A MA049456A MA49456A MA49456A MA 49456 A MA49456 A MA 49456A MA 049456 A MA049456 A MA 049456A MA 49456 A MA49456 A MA 49456A MA 49456 A MA49456 A MA 49456A
Authority
MA
Morocco
Prior art keywords
nafld
nash
compounds
treatment
methods
Prior art date
Application number
MA049456A
Other languages
English (en)
Inventor
John W Adams
Que Liu
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA49456A publication Critical patent/MA49456A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA049456A 2017-06-19 2018-06-19 Composés et procédés pour le traitement de nafld et de nash MA49456A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762522045P 2017-06-19 2017-06-19

Publications (1)

Publication Number Publication Date
MA49456A true MA49456A (fr) 2020-04-29

Family

ID=62875321

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049456A MA49456A (fr) 2017-06-19 2018-06-19 Composés et procédés pour le traitement de nafld et de nash

Country Status (5)

Country Link
US (1) US20200129511A1 (fr)
EP (1) EP3641887A1 (fr)
JP (1) JP2020524181A (fr)
MA (1) MA49456A (fr)
WO (1) WO2018236896A1 (fr)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295573A1 (fr) 1998-11-20 2011-03-16 Arena Pharmaceuticals, Inc. Récepteurs humains orphelins couplés à une protéine g
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
US20070066590A1 (en) 2003-02-24 2007-03-22 Jones Robert M Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7132426B2 (en) 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
ATE415397T1 (de) 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US7833730B2 (en) 2006-04-11 2010-11-16 Arena Pharmaceuticals, Inc. Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2146210A1 (fr) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY
US20100113479A1 (en) 2008-10-30 2010-05-06 Anusuya Choudhury Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
WO2010059385A1 (fr) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Procédé de préparation de dérivés de pyridine tri-substituée et de pyrimidine tri-substituée utiles comme agonistes du récepteur du peptide insulinotrope glucose-dépendant
US20100298362A1 (en) 2009-05-20 2010-11-25 Xun Li Process for the preparation of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
WO2010135505A2 (fr) 2009-05-20 2010-11-25 Janssen Pharmaceutica Nv Forme cristalline de l'ester isopropylique de l'acide 4-[6-(6- méthanesulfonyl-2-méthyl-pyhdin-3-ylamino)-5-méthoxy-pyhmidin-4-yloxy]- pipéridine-1 -carboxylique
HK1243369A1 (zh) * 2015-01-09 2018-07-13 吉利德阿波罗公司 用於治疗非酒精性脂肪肝病的acc抑制剂组合治疗

Also Published As

Publication number Publication date
JP2020524181A (ja) 2020-08-13
EP3641887A1 (fr) 2020-04-29
US20200129511A1 (en) 2020-04-30
WO2018236896A1 (fr) 2018-12-27

Similar Documents

Publication Publication Date Title
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
EP3555077A4 (fr) Compositions et procédés pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3368559A4 (fr) Compositions et méthodes pour le du traitement du cancer
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
EP3359157A4 (fr) Procédés et compositions pour le traitement de tumeurs et de cancers métastasés et résistants
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
IL283200A (en) Combination treatment of nafld and nash
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3478284A4 (fr) Composés et compositions pour le traitement du cancer
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3365014A4 (fr) Méthodes et compositions pour le traitement de la mastocytose systémique
EP3429609A4 (fr) Compositions et procédés pour le traitement de déficits en collagène de type vii